

RETRACTION NOTE

## Retraction Note to: A randomized phase II study of everolimus for advanced pancreatic neuroendocrine tumors in Chinese patients

Jun Yao<sup>1</sup> · Jian-yao Wang<sup>2</sup> · Yi Liu<sup>3</sup> · Bin Wang<sup>2</sup> · Ying-xue Li<sup>1</sup> · Ru Zhang<sup>1</sup> · Li-Sheng Wang<sup>1</sup> · Lei Liu<sup>2</sup>

Published online: 21 July 2015  
© Springer Science+Business Media New York 2015

**Retraction Note to: Med Oncol (2014) 31:251**  
**DOI 10.1007/s12032-014-0251-x**

This article has been retracted by the authors because the authors discovered statistical errors which need further validation.

---

The online version of the original article can be found under doi:[10.1007/s12032-014-0251-x](https://doi.org/10.1007/s12032-014-0251-x).

---

✉ Li-Sheng Wang  
wangls168@163.com

✉ Lei Liu  
liulei3322@yahoo.com.cn

<sup>1</sup> Department of Gastroenterology, Shenzhen Municipal People's Hospital, Jinan University of Medical Sciences, 1017 East Gate Road, Shenzhen 518020, Guangdong Province, China

<sup>2</sup> Department of General Surgery, Shenzhen Children's Hospital, Shenzhen 518026, Guangdong Province, China

<sup>3</sup> Translational Medicine Center, Laboratory of Oncology, Affiliated Hospital of Academy of Military Medical Sciences, Beijing 100071, China